Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?
TheFly reported on June 18 that Jefferies analyst Dennis Ding maintained a Buy rating and a $40 price target on TEVA following recent share weakness.









